W
HEN CARDIOPULMONARY RESUSCITATION (CPR) has to be prolonged for more than 10 to 30 minutes, survival and neurologic outcomes are dismal. 1 This has spurred the institution of rescue extracorporeal membrane oxygenation (ECMO), known as extracorporeal cardiopulmonary resuscitation (ECPR). In this situation, ECMO provides both circulatory and oxygenation support via a system called venoarterial ECMO (VA-ECMO). Vascular access is achieved via the jugular and/or femoral route, and venous blood is drained into the ECMO device, oxygenated, warmed, and pumped back into the arterial system (Fig 1) . An added benefit is that ECPR can facilitate therapeutic interventions that potentially could reverse the cause of the cardiac arrest or collapse (eg, emergent coronary revascularization or relief of cardiac tamponade). ECPR also allows the provision of therapeutic hypothermia by precise blood temperature control.
There is some evidence, most of it from Taiwan, that ECPR in patients suffering from in-hospital cardiac arrest improves both short-and long-term survival when compared with conventional CPR, 2, 3 although this finding has not been consistent. 1 The Extracorporeal Life Support Organization, a worldwide registry of more than 170 centers, 4 has reported a steady increase in the number of patients receiving ECPR over the last 2 decades (Table 1) . 5 Although ECPR potentially may enhance survival and neurologic outcome, a substantial proportion of patients will nonetheless sustain severe neurologic complications, and there is a 1 in 5 chance of brain death. 5 The 3 clinical findings necessary to confirm brain death include coma with a known cause, the absence of brainstem reflexes, and apnea ( Table 2 ). The definitive diagnosis of brain death during ECPR is technically and logistically challenging. Conventional apnea testing is not feasible because oxygenation and carbon dioxide elimination are accomplished by ECMO. The transportation of a patient to the radiology suite for confirmatory tests, such as magnetic resonance imaging or cerebral angiography, potentially can be hazardous.
Establishing a timely diagnosis of brain death avoids prolonged application of extraordinary support with VA-ECMO in a futile situation. Moreover, brain-dead patients on ECMO who sustain adequate end-organ function actually may be considered as potential organ donors. In this report, the indications for and clinical technique of apnea testing specifically adapted to the circulatory support provided by VA-ECMO to determine brain death in patients on ECPR are described.
CASE REPORTS

Case 1
In April 2010, a 78-year-old man with a history of hypertension, hypercholesterolemia, and diabetes presented to the emergency department with worsening midsternal chest pain at rest. He underwent cardiac catheterization during which 2 stents were placed in the left anterior descending artery. Catheterization was complicated by coronary artery perforation, and the patient was transferred to the coronary care unit for further monitoring. Two days later, the patient again complained of chest pain and was taken emergently for repeat cardiac catheterization. During this procedure, the patient suffered a cardiac arrest, and CPR was initiated. Emergency VA-ECMO was placed percutaneously.
The patient was transferred to the cardiothoracic intensive care unit where he was cooled to 33°C for 24 hours and then rewarmed to 37°C. After rewarming, and in the absence of ongoing sedation, the patient remained comatose with an isoelectric electroencephalogram (EEG). Midazolam and propofol infusions were stopped approximately 24 hours before brain death testing. No neuromuscular blockade was used. The patient had normal liver function tests with mild acute kidney injury.
Two consultant neurologists confirmed the absence of brainstem reflexes 6 hours apart. After considerable discussion between the cardiothoracic surgery and intensive care unit (ICU) teams, an apnea test was performed in the following manner. The patient was taken off the mechanical ventilator, and his lungs were insufflated with oxygen. The VA-ECMO pump flow was maintained at 5 L/min, the F I O 2 was maintained at 1.0, and the sweep gas flow (which determines carbon dioxide elimination on ECMO) was lowered to 0.5 L/min. The patient remained apneic without any respiratory effort for 3 minutes, during which time the partial pressure of carbon dioxide in the arterial blood (PaCO 2 ) increased from 41 to 60 mmHg, whereas the partial pressure of oxygen (PaO 2 ) decreased from 177 to 84 mmHg ( Table 3 ). The patient was declared brain-dead and removed from life support.
Case 2
In September 2010, a 55-year-old woman presented for tricuspid valve replacement and a left atrial maze procedure for severe tricuspid regurgitation and atrial fibrillation. Her past medical history was significant for levotransposition of the great arteries, mild pulmonary hypertension, atrial fibrillation, and dilated cardiomyopathy, with New York Heart Association class III heart failure. The surgery was uneventful, with a cardiopulmonary bypass time of 2 hours 13 minutes and an aortic cross-clamp time of 1 hour 24 minutes. Shortly after chest closure in the operating room, the patient became severely hypotensive and required sustained CPR. The patient initially was placed on cardiopulmonary bypass immediately after cardiac arrest and subsequently placed on VA-ECMO because of severe biventricular failure. After ECPR was successful in restoring circulation and oxygenation, the patient was transferred to the cardiothoracic intensive care unit. Therapeutic hypothermia (33°C) was initiated for 24 hours followed by rewarming to 37°C. Upon rewarming, the patient was noted to be unresponsive with an isoelectric EEG. Brain death testing was performed approximately 48 hours after admission to the ICU. The patient had received no sedation or neuromuscular blockade during the ICU stay.
An algorithm for the confirmation of brain death that was identical to that described in case 1 was used. Two consultant neurologists confirmed the absence of brainstem reflexes 6 hours apart. For apnea testing, the patient was taken off the mechanical ventilator, the lungs were insufflated with oxygen, the VA-ECMO pump flow was maintained at 6 L/min with an F I O 2 of 1.0, and the sweep gas flow was decreased to 0.5 L/min. After 10 minutes without respiratory effort, the patient's PaCO 2 increased substantially from 45.3 to 67.5 mmHg, whereas the partial pressure of oxygen decreased minimally, from 142 to 136 mmHg ( Table 3 ). The patient was declared brain-dead. After consent from the patient's health care proxy, she was taken to the operating room for organ retrieval; unfortunately, during laparotomy, none of the organs was considered viable for retrieval.
DISCUSSION
Death is defined by the Uniform Determination of Death Act as "either (i) irreversible cessation of circulatory or respiratory functions, or (ii) irreversible cessation of all functions of the entire brain, including the brain stem . . ." 6 The American Academy of Neurology offers a detailed brain death evaluation protocol. 7 The clinical evaluation includes the documentation of a coma, the absence of brainstem reflexes, and apnea. The determination of a coma requires evidence of a lack of all responsiveness, such as the absence of eye opening, eye movement, or motor response, other than spinally mediated reflexes, to noxious stimuli. Severe elec- trolyte, acid-base, or endocrine disturbance and central nervous system depressant drugs or neuromuscular blockade must be excluded. The presence of central nervous system depressant drugs and neuromuscular blockade must be excluded by reviewing the patient's history, screening for drugs, calculating the clearance using 5 times the drug's half-life, and monitoring the drug plasma level and, in case of neuromuscular blockade, by using a nerve stimulator. 7 Patients' renal and hepatic function should be considered when calculating the drug clearance. For the assessment of brainstem function, the absence of oculocephalic, oculovestibular, corneal, pharyngeal, and laryngeal reflexes should be documented.
The assessment of brainstem function also includes the documentation of absent facial muscle movement to noxious stimuli and the pupillary response to bright light. A positive apnea test is defined by the absence of a respiratory effort at a PaCO 2 Ն60 mmHg or during an increase in PaCO 2 of 20 mmHg from baseline. The prerequisites for an appropriate apnea test are normotension, normothermia, euvolemia, the absence of hypoxemia, and no prior evidence of carbon dioxide retention. Ancillary tests, such as an EEG, nuclear scan, or cerebral angiogram, are considered the preferred tests by the American Academy of Neurology when uncertainty exists about parts of the neurologic examination or when the apnea test cannot be performed. 7 An EEG is a reliable test that is used commonly in confirming the clinical signs of brain death. However, some common problems associated with recording an EEG in the ICU are the presence of electromagnetic fields that might interfere with the tracing and the presence of the residual level of sedative drugs in the blood. The EEG should be recorded continuously for at least 30 minutes to show irreversible bioelectric silence. Tests, such as a nuclear scan and angiography, are used to show cerebral circulatory arrest. 8 There are no published guidelines for diagnosing brain death in patients being supported with VA-ECMO. Performing an apnea test in patients on ECMO can be challenging, and many physicians consider it too difficult to perform. 9 When a patient with poor pulmonary gas exchange is disconnected from the ventilator to perform the apnea test, poorly oxygenated blood returning from the lungs to the left side of the heart rapidly causes hypoxemia. Decreasing the sweep gas flow on ECMO can reliably increase the patient's PaCO 2 . However, if the sweep gas flow is too low, hypoxemia will ensue before the PaCO 2 increases sufficiently to permit the documentation of brain death. The alternative assessments of cerebral angiography or nuclear scanning usually are excluded because it is hazardous to transport patients on ECMO.
The present authors' approach is supported by the recommendations made by Muralidharan et al 9 in a recent article that was published after the apnea test was performed in the patients described here. They reported 3 cases in which apnea testing was considered too difficult or impossible to perform in patients with suspected brain death on VA-ECMO that had been placed for ECPR. The authors proposed an approach that includes all the elements used in the present cases including continuous lung insufflation at an F I O 2 of 1.0 and the lowest possible oxygenator sweep flow to maintain an oxygenation saturation Ͼ90%. After a baseline arterial blood gas confirms eucapnia (PaCO 2 ϭ 35-45 mmHg), apnea is confirmed by the absence of respiratory effort with a 20-mmHg increase in PaCO 2 or when an absolute PaCO 2 of 60 mmHg is achieved. The present authors were able to successfully perform the apnea test using similar methodology in both patients before the publication of the article by Muralidharan et al 9 in which they deemed the apnea test too difficult to perform in 3 patients on VA-ECMO.
In conclusion, all evidence suggests that the incidence of ECPR is increasing and that more patients will be encountered with severe neurologic injury and brain death on VA-ECMO. The acceptance of a standardized approach to apnea testing as proposed by Muralidharan et al 9 and successfully used by clinicians would expedite and strengthen a timely diagnosis of brain death. The early clarification of patient outcome coupled with end-of-life counseling may address the emotional distress caused by uncertainty, thus enabling the family to move forward in the process of grief. It also will enable these patients to be referred earlier for possible organ donation when ECPR is unable to render a good outcome.
